Choueiri, T. K., Flaifel, A., Xie, W., Braun, D., Ficial, M., Jennings, R., … Signoretti, S. (2018). PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. In Ann Oncol (Vol. 29 Suppl 8, p. viii726). England. https://doi.org/10.1093/annonc/mdy424.040

Choueiri, T. K., A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, et al. “PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.” In Ann Oncol, 29 Suppl 8:viii726, 2018. https://doi.org/10.1093/annonc/mdy424.040.

Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, et al. PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. In: Ann Oncol. 2018. p. viii726.

Choueiri, T. K., et al. “PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii726. Pubmed, doi:10.1093/annonc/mdy424.040.

Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman G, Signoretti S. PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. Ann Oncol. 2018. p. viii726.